Highlights Chronic Airway Therapeutics (CAT) selects R&G Pharma to progress Chinese development of nadolol R&G is one of China’s leading Contract Research Organisations CAT, R&G ready to commence regulatory process and will request pre-IND meeting with China Food and Drug Administration Melbourne, Australia and Delaware, United States, 27 September 2018: Chronic Airway Therapeutics (CAT), a…
Read more
New formulation of Photosoft therapy shows increased effect in ovarian cancer
New in vitro data shows effectiveness of IVX-P02, an improved formulation of Photosoft™ Oral IVX-P02 is 15 times more effective than Photosoft™ Oral at killing ovarian cancer cells in vivo animal trials to be commenced this year, moving to human clinical trials in 2019 Melbourne, Australia, 25 September 2018: Cancer therapy developer Invion Limited (ASX:…
Read more
Photosoft granted patent protection in Australia
Invion’s licensed PhotosoftTM technology receives patent protection until 2033 PhotosoftTM targeted as a therapy for a range of cancers including ovarian, lung, skin and prostate cancer Melbourne, Australia, 10 September 2018: ASX-listed life sciences company Invion Limited (ASX:IVX) announces the grant in Australia of the patent for chlorin e4 sodium, a new generation photodynamic therapy…
Read more
Invion to spinout respiratory assets and advance clinical development in China
Invion to demerge respiratory assets into stand-alone company, Chronic Airway Therapeutics Limited (CAT) CAT to focus on development of respiratory assets in China, expediting advancement into Phase 3 clinical trials Eligible Invion shareholders will, on completion of the demerger, receive one share in Chronic Airway Therapeutics Limited for each Invion share they hold Melbourne, Australia…
Read more